Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Go back to Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting| (NASDAQ: PTGX) | Delayed: 115.03 +2.17 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $112.86 | 52 Week High | $24.52 | |||
| Open | $113.24 | 52 Week Low | $10.02 | |||
| Day High | $116.57 | P/E | N/A | |||
| Day Low | $113.24 | EPS | $0.00 | |||
| Volume | 1,193,689 | |||||
